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Objectives:Our objective was to explore the pathologic components of residual masses after primary chemother-
apy in patients with metastatic nonseminomatous germ cell tumors.
Methods: A multicenter retrospective study was conducted of 71 patients with thoracic residual masses (39 pa-
tients had bilateral lung metastasis) after first-line cisplatin-based chemotherapy for disseminated nonseminom-
atous germ cell tumors. Among the 71 patients, 52 also had a retroperitoneal lymph node dissection.
Results: Pathologic findings in postchemotherapy residual masses included complete necrosis, teratoma, and vi-
able cancer in 31%, 55%, and 14% of patients, respectively. Discordant pathologic findings were evidenced be-
tween retroperitoneal lymph node and thoracic (lung or mediastinal lymph nodes) residual masses in 27% of
patients. When a bilateral pulmonary resection was performed, only 2 (5%) of 39 patients had discordant histo-
logic findings between the two lungs. Among patients who had necrosis only in residual masses from their first
lung (n ¼ 20), 19 (95%) also had necrosis only in contralateral lesions. A single patient had necrosis only in the
first lung and some teratoma in the contralateral lung.
Conclusions: This report shows a high rate (95%) of pathologic concordance between the two lungs. Avoiding
contralateral lung surgery could therefore be considered when complete necrosis is found in the first lung after
induction chemotherapy for nonseminomatous germ cell tumor.Multimodality treatments combining cisplatin-based che-
motherapy and surgery cure about 80% of patients with
advanced nonseminomatous germ cell tumor (NSGCT).1
Guidelines promote tailoring induction chemotherapy to
the prognostic groups identified in the International Germ
Cell Consensus Classification (IGCCCG) and using serum
tumor markers to monitor its efficacy.2,3 At normalization
of serum tumor markers after chemotherapy, about one third
to one half of patients have residual masses at radiologic as-
sessment. The largest surgical studies have shown that resid-
ual masses contain viable tumor cells and teratoma in 12%
to 15% and 34% to 42% of cases, respectively.4-13 More-
over, comparative pathologic analysis of retroperitonal
lymph node dissection (RPLND) specimens and lung metas-
tases has unveiled a discordance in lesion components in
28% to 36% of cases8,11,13,14 Complete necrosis is found
in residual lung masses in a relatively high proportion of
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serum tumor markers after chemotherapy.8,11,13,14 Extensive
resection of all residual masses is therefore currently recom-
mended by most authors. However, in this setting, surgical
complications range from 6% for an isolated lung metastasis
and 8% for an isolated RPLND to 13% for mediastinal re-
section or 35% for a sequential RPLND and thoracic resec-
tion.15-18 use and the cumulative dose of bleomycin were
shown to be correlated with increased lung surgery–related
morbidity and mortality, particularly in patients requiring
major pulmonary resections.19
This prompted our decision to conduct this retrospective
study of patients with metastatic NSGCT after normalization
of tumor markers to (1) confirm the discrepancy of histologic
findings between thoracic and retroperitoneal residual
masses, (2) correlate histologic findings in mediastinal le-
sions with those found in retroperitonal or lung lesions,
due to the lack of published data,14 and (3) compare histo-
logic findings between ipsilateral and contralateral lung le-
sions to determine whether contralateral lung surgery is
necessary when necrosis only is found in postchemotherapy
residual lung masses.
METHODS AND PATIENTS
This is a French multicenter retrospective study. Eligibility criteria in-
cluded the following: male patients treated consecutively from January
1980 to January 2003, histologically proven metastatic NSGCT (or the di-
agnosis based on elevated serum markers and a presentation compatible
with a metastatic germ cell tumor [GCT]), first-line cisplatin-based chemo-
therapy, and evidence of residual masses after first-line chemotherapy: (1)gery c February 2009
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CI ¼ confidence interval
GCT ¼ germ cell tumor
IGCCCG ¼ International Germ Cell Consensus
Classification
NSGCT ¼ nonseminomatous germ cell tumor
OS ¼ overall survival
PFS ¼ progression-free survival
RPLND ¼ retroperitonal lymph node dissection
thoracic (either lung or mediastinal lymph node metastases) and retroperito-
neal masses or (2) bilateral thoracic lesions. Patients with metastatic primary
mediastinal tumors were not included. In addition, normalized serum tumor
markers, including alfa-fetoprotein (AFP), human chorionic gonadotropin
(HCG), and lactate dehydrogenase (LDH) in all cases, were required at
the time of postchemotherapy surgery. Surgical management could include
partial or complete excision of residual masses and, if reoperation was
performed, the interval between the two operations had to be less than 4
months. No additional chemotherapy was allowed between the first and
last resections. Patients with residual viable NSGCT containing malignant
non-GCT neoplasms such as sarcoma and adenocarcinoma, usually called
‘‘teratoma with malignant transformation,’’20 were included in this study.
Investigators were asked to provide pathologic data on the primary tumor,
the prognostic group according to the IGCCCG classification,21 the type
of first-line chemotherapy, postchemotherapy normalization of serum tumor
markers, sites concerned by postchemotherapy surgery, pathologic analysis
of residual masses, surgery-related mortality, follow-up information includ-
ing data on relapse and survival, and the incidence of the growing teratoma
syndrome.22 Data collection was finalized in July 2004. Shrinkage was cal-
culated as the percentage of change in the maximum diameter of a mass. The
model developed by Steyerberg and associates,11 which identifies sub-
groups of patients with a high probability of necrosis, was applied in this
series. Progression-free survival (PFS) was defined as the time from ran-
domization until objective tumor progression or death. PFS and overall
survival (OS) rates were estimated by the Kaplan–Meier method. For the
analysis of survival, follow-up started on the date of postchemotherapy sur-
gery. This research was conducted within the framework of the Internal
Review Board (Commission Scientifique des Essais The´rapeutiques de l’In-
stitut Gustave Roussy).
RESULTS
Patient Characteristics and Treatment
Five institutions participated in the study. Seventy-one
patients fulfilling study criteria were recruited over a 23-
year period. Patient characteristics and first-line chemother-
apy regimens are listed in Table 1. The median number of
chemotherapy cycles was 4 (range 3–12). Tumor markers
had normalized after the first regimen in 57 (80%) patients.
The first surgical resection of residual masses was performed
after a median period of 44 days after chemotherapy (range
10–121 days). Fifty (70%) and 11 (15%) patients under-
went a second and a third resection after a median period
of 47 and 41 days, respectively. Surgical procedures are
summarized in Figure 1. Fifty-two (73%) patients under-
went both RPLND and a thoracotomy, including 29 who
had a resection of pulmonary metastases, 16 who had a resec-The Journal of Thoracic and Ction of mediastinal lymph nodes, and 7 who had both oper-
ations. Resection of bilateral lung lesions and mediastinal
lymph node metastases was achieved in 39 and 28 patients,
respectively. Bilateral lung surgery was performed by ster-
notomy in 4 patients and bilateral thoracotomies in 34 pa-
tients (missing data for 1 patient). Bilateral thoracotomies
were sequential in 25 patients (median time between opera-
tions was 13 days), whereas it was performed during the
same procedure in 9 patients.
Pathology
Pathologic findings in residual lesions included complete
necrosis, teratoma, immature teratoma, and viable cancer in
31%, 39%, 16%, and 14% of patients, respectively. The
TABLE 1. Patient characteristics
Patients (n ¼ 71)
Characteristics No. %
Age, y
Median 26.8
Range 17–43
Primary tumor site
Testis 67 94
Retroperitoneum 4 6
Pathologic components in the primary tumor
Seminoma 7 10
Embryonal carcinoma 45 63
Yolk sac tumor 30 42
Choriocarcinoma 26 37
Teratoma 37 52
Immature teratoma 21 30
Other 1 1
Serum markers prior to initial chemotherapy
HCG, IU/L
Median 277,5
Range 0–1,000,000
Missing values 6 8
AFP, ng/mL
Median 106
Range 0–40,927
Missing values 4 6
LDH, IU/L
Median 1.88 N
Range 0–26 N
Missing values 18 25
IGCCCG
Favorable 17 30
Intermediate 15 27
Poor 24 43
Missing data 15
First-line chemotherapy regimen
BEP 48 67
EP 7 10
Other 16 23
AFP, Alfa-fetoprotein; BEP, etoposide, cisplatin, bleomycin; EP, etoposide, cisplatin;
HCG, human chorionic gonadotropin; IGCCCG, International Germ Cell Consensus
Classification; LDH, lactate dehydrogenase.ardiovascular Surgery c Volume 137, Number 2 449
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logical discordances are summarized in Figure 2. The over-
all rate of pathologic discordance (complete necrosis vs
teratoma vs viable cancer) between retroperitoneal lymph
node and thoracic (lung or mediastinal lymph nodes) resid-
ual masses was 27% (n ¼ 14/52). In patients who had both
a resection of lung metastases and RPLND (n¼ 36), the dis-
cordance rate was 33% (n¼ 12). The more aggressive path-
ologic component was found in the retroperitoneal lymph
nodes in 9 (25%) patients and in the lung in 3 (8%) patients.
Among 15 patients who had complete necrosis in retroperi-
toneal lymph nodes, pathologic findings in their lung metas-
tases were as follows: complete necrosis (n ¼ 12, 80%),
teratoma (n ¼ 2), and cancer cells (n ¼ 1). In patients who
underwent resection of both mediastinal and retroperitoneal
lymph nodes (n ¼ 23), the discordance rate was 17% (n ¼
4); the more aggressive pathologic component was found
in the retroperitoneal lymph nodes in 3 patients. Pathologic
findings were discordant in 4 (33%) of 12 patients who
underwent resection of both mediastinal lymph nodes and
pulmonary metastases.
In contrast, only 2 (5%) of the 39 patients who underwent
a resection of ipsilateral and contralateral pulmonary metas-
tases had discordant pathologic findings between the two
lungs. The first of these 2 patients was classified in the
good prognostic group according to IGCCCG and was
treated with 4 cycles of cisplatin and etoposide. Metastases
from both lungs contained teratoma, but only pulmonary
metastases located in the right lung also contained yolk
sac tumor. The second patient was treated with 4 cycles of
cisplatin, bleomycin, and etoposide followed by high-dose
chemotherapy for an intermediate prognosis NSGCT. The
pathologic examination of residual masses found complete
necrosis in retroperitoneal and mediastinal lymph nodes
and also in the pulmonary metastases located in the right
lung, whereas the contralateral lung also contained some ter-
atoma. Among 20 patients who had complete necrosis in the
residual masses in the first operated lung, 19 (95%) also had
complete necrosis in the residual masses from the contralat-
eral lung.
Retroperitoneal lymph node
dissection (n=52)
Lung
metastasis
resection
(n=53)
Mediastinal
metastasis
resection
(n=28)
29
7
16
5
37
bilateral
FIGURE 1. Distribution of surgical procedures among the 71 pts included.450 The Journal of Thoracic and Cardiovascular SuSurvival and Factors Predictive of Necrosis in Lung
Lesions
Survival. After a median follow-up of 5.6 years (range
0.6–19.7), the 5-year PFS was 65% (95% confidence inter-
val [CI], 59%–72%) and the 5-year OS was 94% (95% CI,
91%–97%). Eleven (15%) and 11 (15%) patients had a re-
current malignant NSGCT and growing teratoma syndrome,
respectively. Among the 39 patients with bilateral lung re-
section, 9 had recurrence including 4 with growing teratoma
syndrome; site of recurrence was only lung in 3 patients,
lung and other site in 3 patients, and others site in 2 patients
(missing data for 1 patient). Of 16 patients with unilateral
lung resection, none had contralateral residual nodules, 1
has a mediastinal recurrence, and 3 extrathoracic
TABLE 2. Tumor characteristics and pathologic analyses of residual
pulmonary masses
Necrosis Teratoma Cancer Total
No. % No. % No. % No. %
Primary tumor histology
Teratoma negative 9 36 12 48 4 16 25 50
Teratoma positive 17 68 4 16 4 16 25 50
Prechemotherapy AFP
(ng/mL)
Normal 5 50 3 30 2 20 10 24
Elevated 16 50 9 28 7 22 32 76
Prechemotherapy HCG
(IU/L)
<1,000 13 45 11 38 5 17 29 61
1,000–10,000 2 40 1 20 2 40 5 10
>10,000 14 100 0 0 0 0 14 29
IGCCCG
Good 3 23 8 62 2 15 13 33
Intermediate 6 67 2 22 1 11 9 22
Poor 16 84 1 5 2 11 19 45
Steyerberg score
>95% necrosis 13 100 0 0 0 0 13 24
Histology at RPLND
Necrosis 12 80 2 13 1 7 15 47
Teratoma 5 42 7 58 0 0 12 38
Cancer 4 44 2 22 3 33 9 28
Histology at contralateral
lung resection
Necrosis 19 95 1 5 0 0 20 51
Teratoma 0 0 12 100 0 0 12 31
Cancer 0 0 1 14 6 86 7 18
Shrinkage
Retroperitoneal lymph
nodes
50% 8 80 2 20 0 0 10 59
<50% 8 47 6 35 3 18 17 41
Lung metastasis
50% 7 44 7 44 2 12 16 48
<50% 7 41 4 23 6 36 17 52
AFP, Alfa-fetoprotein HCG, human chorionic gonadotropin; IGCCCG, International
Germ Cell Consensus Classification; RPLND, retroperitonal lymph node dissection.rgery c February 2009
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progression.
Shrinkage. Shrinkage was not correlated with OS or PFS.
However, shrinkage was well correlated with the percentage
of complete necrosis in retroperitoneal lymph nodes but not
in lung metastases (Table 2).
Predictive model of complete necrosis. Among the 13
(24%) patients who fit Steyerberg’s subgroup criteria indi-
cating a likelihood of complete necrosis in excess of 90%
according to this model, complete necrosis was found in
lung metastases in all cases (Table 2).
DISCUSSION
The discrepancy in pathologic findings between postche-
motherapy residual retroperitoneal and pulmonary masses in
patients with disseminated NSGCT has been extensively re-
ported, and our results (a concordance rate of only 67%) are
consistent with previously published data.8,11,13,14 Although
the numbers are too small to allow firm conclusions, post-
chemotherapy residual mediastinal lymph node masses
seem to be quite similar to residual retroperitoneal masses
with a pathologic concordance rate of 83% (95% CI,
61%–95%), which contrasts with a pathologic concordance
rate of only 67% (95% CI, 35%–90%) for residual pulmo-
nary masses. The similarity in pathologic findings between
residual retroperitoneal and mediastinal masses is likely to
be explained by the route of lymphatic drainage from the ret-
roperitoneum directly into the visceral mediastinum via the
thoracic duct. Although data in the literature are scarce
and limited regarding pathologic findings between residual
mediastinal and pulmonary masses,14,20,23 the discrepancy
we found has previously been suggested.14
To our knowledge, no published study has focused specif-
ically on the pathologic analysis of residual ipsilateral and
contralateral lung masses; hitherto, only anecdotal cases
have been reported.7,14 The high rate (95% CI, 83%–
99%, n ¼ 39) of pathologic concordance between residual
masses from the two lungs found in this study is potentially
an important finding given the alleged paucity of reports on
the subject. Of 20 patients with complete necrosis in residual
DISCORDANCE RATE
0% 5% 10% 15% 20% 25% 30% 35%
RPLN  - LUNG
LUNG  - LUNG
MED.  - LUNG
RPLN  - MED.
FIGURE 2. Pathological discordance rate among the residual sites. RPLN,
Retroperitoneal lymph nodes; MED., mediastinal lesions.The Journal of Thoracic and Cmasses in the first lung, 19 (95%) also had complete necro-
sis in residual masses in the contralateral lung. The practical
consequences may include surveillance of the contralateral
lung in such patients, rather than resection of contralateral
masses, thus avoiding significant morbidity and allowing
substantial cost savings.
Unfortunately, the models currently available to predict
complete necrosis in residual lesions are not considered accu-
rate enough. In a multicentric series of 215 patients with dis-
seminated NSGCT and postchemotherapy residual masses,
Steyerberg and associates11 identified subgroups of patients
with a high likelihood of necrosis at thoracotomy. However,
an attempt to validate this predictive model failed; only
a 76% complete necrosis rate was obtained in a series of 70 pa-
tients in whom the predicted probability of complete necrosis
in residual pulmonary masses was 93%.8 New methods are be-
ing investigated to predict pathologic findings in residual
masses. The use of positron emission tomography with 2-(fluo-
rine-18)-fluoro-2-deoxy-D-glucose has been investigated. Un-
fortunately, the absence of tracer uptake did not correlate with
complete necrosis in 37% to 58% of cases in NSGCT.23,24
Gene expression profiling in NSGCT may be a useful tool
for the selection of chemosensitive tumors, but it has not
been validated in postchemotherapy residual masses.25
In conclusion, we found a 95% rate of pathologic concor-
dance between residual ipsilateral and contralateral pulmo-
nary masses after chemotherapy in patients with metastatic
NSGCT. This result raises the question of surveillance
alone, rather than a contralateral thoracotomy in patients in
whom complete necrosis is found in residual masses from
the first lung, to avoid unnecessary morbidity. We proposed
a renewed algorithm for the surgical management of patients
with metastatic NSGCT (Figure 3).
Metastatic non seminomatous germ  cell tumor
After induction chemotherapy
And normalization of tumor markers 
+ surgery of all others residual site
(retroperitoeal, mediastinal…)
+ Lung residual lesions
Unilateral Bilateral
Lung surgery First side lung surgery
Necrosis :
watchful waiting
Teratoma or viable 
cells : 
surgery of contra-
lateral lung
FIGURE 3. Proposed algorithm for residual lung lesions.ardiovascular Surgery c Volume 137, Number 2 451
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